It therefore results that C-MIC has the potential to successfully treat patients with HFrEF (heart failure with reduced ejection fraction) as well as patients with HFpEF (heart failure with preserved ejection fraction). According to pre-clinical research, even patients suffering from ischemic heart disease may be treated successfully.
Macfelda et al 2017
ncbi.nlm.nih.gov/pmc/articles/PMC5542736
Kappeler et al 2016
ncbi.nlm.nih.gov/pubmed/27774272